213 related articles for article (PubMed ID: 25831706)
1. [Using recombinant activated blood coagulation factor VII for treatment of hemorrhagic syndrome in patients with thrombocytopenia].
Galstian GM; Kolosova IV
Anesteziol Reanimatol; 2014; 59(6):60-6. PubMed ID: 25831706
[TBL] [Abstract][Full Text] [Related]
2. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
3. [Application of activated recombinant factor VII (rFVIIa, NovoSeven) in neonatology].
Georgieva R
Akush Ginekol (Sofiia); 2008; 47(3):46-50. PubMed ID: 18756832
[TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center.
Sartori MT; Imbergamo S; Zanon E; Bonaccorso G; Pittoni G; Feltracco P; Ori C; Pagnan A; Cella G
Clin Appl Thromb Hemost; 2009 Dec; 15(6):628-35. PubMed ID: 19605376
[TBL] [Abstract][Full Text] [Related]
5. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.
Hedner U; Glazer S; Falch J
Transfus Med Rev; 1993 Apr; 7(2):78-83. PubMed ID: 8481602
[TBL] [Abstract][Full Text] [Related]
6. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
Poon MC
Curr Hematol Rep; 2003 Mar; 2(2):139-47. PubMed ID: 12901145
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.
Palmason R; Vidarsson B; Sigvaldason K; Ingimarsson JP; Gudbjartsson T; Sigurdsson GH; Onundarson PT
Acta Anaesthesiol Scand; 2012 May; 56(5):636-44. PubMed ID: 22489992
[TBL] [Abstract][Full Text] [Related]
8. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review.
Long MT; Wagner D; Maslach-Hubbard A; Pasko DA; Baldridge P; Annich GM
Perfusion; 2014 Mar; 29(2):163-70. PubMed ID: 23942787
[TBL] [Abstract][Full Text] [Related]
10. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
Laurian Y
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():37-40. PubMed ID: 12214146
[TBL] [Abstract][Full Text] [Related]
11. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
12. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.
Gerotziafas GT; Zervas C; Gavrielidis G; Tokmaktsis A; Hatjiharissi E; Papaioannou M; Lazaridou A; Constantinou N; Samama MM; Christakis J
Am J Hematol; 2002 Mar; 69(3):219-22. PubMed ID: 11891811
[TBL] [Abstract][Full Text] [Related]
13. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects.
Skolnick BE; Mathews DR; Khutoryansky NM; Pusateri AE; Carr ME
Blood; 2010 Aug; 116(5):693-701. PubMed ID: 20385794
[TBL] [Abstract][Full Text] [Related]
14. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
[TBL] [Abstract][Full Text] [Related]
15. The use of recombinant activated factor VII in platelet-associated bleeding.
Franchini M; Lippi G; Guidi GC
Hematology; 2008 Feb; 13(1):41-5. PubMed ID: 18534065
[TBL] [Abstract][Full Text] [Related]
16. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
[TBL] [Abstract][Full Text] [Related]
17. [Use of recombinant activated factor VII].
Reingardiene D; Lazauskas R
Medicina (Kaunas); 2009; 45(3):248-53. PubMed ID: 19357455
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits.
Tranholm M; Rojkjaer R; Pyke C; Kristensen AT; Klitgaard B; Lollike K; Blajchman MA
Thromb Res; 2003 Feb; 109(4):217-23. PubMed ID: 12757777
[TBL] [Abstract][Full Text] [Related]
19. [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
Levi M; Friederich PW; van der Meer J
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2534-7. PubMed ID: 12532665
[TBL] [Abstract][Full Text] [Related]
20. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.
Spinella PC; Perkins JG; McLaughlin DF; Niles SE; Grathwohl KW; Beekley AC; Salinas J; Mehta S; Wade CE; Holcomb JB
J Trauma; 2008 Feb; 64(2):286-93; discussion 293-4. PubMed ID: 18301188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
